Heymach J, et al. A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). IASLC 2018; abstract OA02.06.
Dankzij 3D-technologie kan nier vaker blijven zitten
aug 2024 | Uro-oncologie
feb 2024 | Longoncologie
dec 2023 | Uro-oncologie
dec 2022 | Maag-darm-leveroncologie
jun 2021 | Chirurgie, Maag-darm-leveroncologie
feb 2021 | Maag-darm-leveroncologie
sep 2024
jul 2024
jun 2024
mrt 2024